Anti-ErbB3 [RTJ2] mAb

Please Enter Your Email ID
Email ID

Cat. #151158

Anti-ErbB3 [RTJ2] mAb

Cat. #: 151158

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: ErbB3 (Her3)

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Bill Gullick

Institute: University College London (UCL), UK

Primary Citation: Benterud et al. 1976. Tidsskr Nor Laegeforen. 96(31):1647-1648. PMID: 982398.

Tool Details
Target Details

Tool Details


  • Name: Anti-ErbB3 [RTJ2] mAb
  • Alternate name: Anti-ErbB3 antibody
  • Research fields: Cancer;Cell biology;Cell signaling and signal transduction
  • Clone: RTJ2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IF ; IP ; WB
  • Description: Anti-ErbB3 [RTJ2] is a monoclonal antibody which binds ErbB3. ErbB3 (c-erbB-3/HER-3) is a type I growth factor receptor and binds to ligands in the heregulin family. ErbB3 is over-expressed in a variety of tumours in the bladder, breast, colon, pancreas and stomach. By immunoprecipitation, this antibody detects a protein representing HER-3 from human tissue extracts. This antibody has also been used in immunohistochemistry, immunofluorescence, western blotting and ELISA procedures using human tissues.
  • Immunogen: Synthetic peptide of human ErbB3
  • Immunogen uniprot id: P21860
  • Isotype: IgG1
  • Myeloma used: NS0

Target Details

  • Target: ErbB3 (Her3)
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB3 is normally found in non-dividing differentiated epithelial cells, neurones and hepatocytes. It has approximately 80% prevalence in a wide variety of tumours of the gastro-intestinal tract, and approximately 20% prevalence in breast cancer.


  • Application: ELISA ; FACS ; IHC ; IF ; IP ; WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C


  • Almadori et al. 2010. Eur J Cancer. 46(6):1144-1152. PMID: 20149638.
  • Anagnostou et al. 2010. Cancer Epidemiol Biomarkers Prev. 19(4):982-991. PMID: 20332259.
  • Okwueze et al. 2007. J Invest Dermatol. 127(5):1030-1041. PMID: 17124505.
  • Srinivasan et al. 1998. J Pathol. 185(3):236-245. PMID: 9771476.
  • Rajkumar et al. 1995. Int J Oncol. 6(1):105-109. PMID: 21556509.
  • Benterud et al. 1976. Tidsskr Nor Laegeforen. 96(31):1647-1648. PMID: 982398.